Virtus Fund Advisers, LLC Halozyme Therapeutics, Inc. Transaction History
Virtus Fund Advisers, LLC
- $28 Million
- Q1 2024
A detailed history of Virtus Fund Advisers, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Virtus Fund Advisers, LLC holds 750 shares of HALO stock, worth $40,530. This represents 0.11% of its overall portfolio holdings.
Number of Shares
750
Previous 750
-0.0%
Holding current value
$40,530
Previous $27,000
11.11%
% of portfolio
0.11%
Previous 0.17%
Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
450Shares Held
123MCall Options Held
216KPut Options Held
129K-
Black Rock Inc. New York, NY18.2MShares$986 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$705 Million0.01% of portfolio
-
State Street Corp Boston, MA6.49MShares$351 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.12MShares$222 Million3.73% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.79MShares$205 Million0.24% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.53B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...